Mondo Visione Worldwide Financial Markets Intelligence

FTSE Mondo Visione Exchanges Index:

NYSE Euronext Announces Trading Volumes For April 2012 - Global Derivatives ADV In April Down 7% Year-Over-Year; Up 9% From 1Q12 Levels - #1 In U.S. Equity Options In April; Record Monthly Market Share For NYSE Amex Options - April European Cash ADV Up 23% And U.S. Cash ADV Down 13% Year-Over-Year

Date 08/05/2012

NYSE Euronext (NYX) today announced trading volumes for its global derivatives and cash equities exchanges for April 20121. Trading volumes were mixed both year-over-year and month-over-month across most venues, but reflected some strengthening relative to weak first quarter 2012 levels. Global derivatives average daily volume ("ADV") of 8.2 million contracts in April 2012 decreased 6.9% versus the prior year, but increased 1.4% from March 2012 and increased 9.0% from first quarter 2012 levels. European cash trading ADV in April increased 22.8% versus the prior year, increased 14.8% from March 2012 levels and increased 17.8% from first quarter 2012 levels. U.S. cash trading ADV decreased 13.3% and 2.5% from April 2011 and March 2012 levels, respectively, and declined 3.6% from first quarter 2012 levels.

Highlights

 

  • NYSE Euronext global derivatives ADV in April 2012 of 8.2 million contracts decreased 6.9% compared to April 2011, but increased 1.4% from March 2012 levels and were up 9.0% from first quarter 2012 levels.
  • NYSE Euronext European derivatives products ADV in April 2012 of 4.3 million contracts decreased 9.6% compared to April 2011, but increased 9.1% from March 2012 and were up 28.2% from first quarter 2012 levels. Excluding Bclear, NYSE Liffe's trade administration and clearing service for OTC products, European derivatives products ADV decreased 2.8% compared to April 2011, were in-line with March 2012 and increased 5.3% from first quarter 2012 levels.
  • NYSE Euronext U.S. equity options ADV of 3.9 million contracts in April 2012 decreased 3.3% compared to April 2011 levels, decreased 4.9% from March 2012 and decreased 5.5% from first quarter 2012 levels. NYSE Euronext's U.S. options exchanges accounted for 26.4% of total U.S. consolidated equity options trading in April 2012, up from 25.7% in April 2011 and up from 26.0% in March 2012. NYSE Euronext was the #1 U.S. equity options exchange operator in April 2012 and NYSE Amex Options recorded record monthly market share of 15.8%.
  • NYSE Liffe U.S. ADV of approximately 61,500 contracts decreased from 91,700 contracts in April 2011 and decreased from 104,900 contracts in March 2012.
  • NYSE Euronext European cash products ADV of 1.9 million transactions in April 2012 increased 22.8% compared to April 2011 and increased 14.8% from March 2012 levels. European cash products ADV in April 2012 was 17.8% above first quarter 2012 levels.
  • NYSE Euronext U.S. cash products handled ADV of 1.7 billion shares in April 2012 decreased 13.3% compared to April 2011 and decreased 2.5% compared to March 2012. U.S. cash products handled ADV in April 2012 was 3.6% below first quarter 2012 levels. NYSE Euronext's Tape A matched market share in April 2012 was 31.3%, down from 33.3% in April 2011, in-line with March 2012 and above the 30.6% recorded in the first quarter of 2012.
  • There were a total of 19 trading days in Europe and 20 trading days in the U.S. in April 2012 and April 2011.

 

Derivatives Trading

European Derivatives

 

  • NYSE Euronext European derivatives products ADV in April 2012 of 4.3 million contracts decreased 9.6% compared to April 2011, but increased 9.1% from March 2012 levels and was up 28.2% from first quarter 2012 levels.
  • The 4.3 million in European derivatives futures and options contracts ADV in April 2012 consisted of 2.8 million contracts executed through our full-service LIFFE CONNECT trading platform and 1.5 million contracts, or 34.4%, executed through Bclear, NYSE Liffe's trade administration and clearing service for OTC products. Excluding Bclear, NYSE Liffe's trade administration and clearing service for OTC products, European derivatives products ADV decreased 2.8% compared to April 2011, were in-line with March 2012 and increased 5.3% from first quarter 2012 levels.
  • Year-to-date, European derivatives products ADV of 3.5 million contracts was 23.8% below prior year levels. The 3.5 million in futures and options contracts ADV year-to-date consisted of 2.7 million contracts executed through LIFFE CONNECT trading platform and 0.8 million contracts, or 24.1%, executed through Bclear.
  • Total fixed income products ADV of 1.8 million contracts in April 2012 decreased 7.1% from April 2011, decreased 4.5% from March 2012, but were 1.0% above first quarter 2012 levels. Year-to-date, total fixed income products ADV of 1.8 million contracts was 29.5% below prior year levels.
  • Total equity products (including Bclear) ADV of 2.4 million contracts in April 2012 decreased 11.7% compared to April 2011, but increased 22.6% from March 2012. The 2.4 million contracts in equity products ADV consisted of 1.8 million contracts in individual equity products ADV and 0.6 million contracts in equity index products ADV. The 2.4 million contracts in individual equity products ADV consisted of 1.3 million in futures contracts, which represented a 24.6% decrease compared to April 2011 and 0.5 million in options contracts, which represented a 4.8% increase compared to April 2011. The average net rate per contract for individual equity futures contracts is significantly lower than other European derivatives products. Year-to-date, total equity products ADV of 1.7 million contracts was 17.6% below prior year levels.
  • Total commodities products ADV of approximately 81,000 contracts in April 2012 increased 4.7% compared to April 2011 and decreased 1.2% compared to March 2012. Year-to-date, total commodities product ADV of 81,000 contracts was 4.9% below prior year levels.

 

U.S. Derivatives

 

  • NYSE Euronext U.S. equity options ADV of 3.9 million contracts in April 2012 decreased 3.3% compared to April 2011, decreased 4.9% compared to March 2012 and were 5.5% below first quarter 2012 levels. Year-to-date, U.S. equity options ADV of 4.1 million contracts was 5.7% below prior year levels.
  • Total U.S. consolidated equity options ADV decreased 5.9% to 14.8 million contracts in April 2012 compared to April 2011 and decreased 6.6% compared to March 2012. Year-to-date, U.S. consolidated equity options ADV of 15.6 million contracts was 7.7% below prior year levels.
  • NYSE Euronext's U.S. options exchanges accounted for 26.4% of the total U.S. consolidated equity options trading in April 2012, up from 25.7% in April 2011 and up from 26.0% in March 2012. NYSE Euronext was the #1 U.S. equity options exchange operator in April 2012 and NYSE Amex Options recorded record monthly market share of 15.8%.
  • NYSE Liffe U.S. ADV of approximately 61,500 contracts decreased from 91,700 contracts in April 2011 and decreased from 104,900 contracts in March 2012. Year-to-date, U.S. futures and futures options ADV of 87,700 contracts was 131.7% above prior year levels.

 

Cash Trading

European Cash

 

  • NYSE Euronext European cash products ADV of 1.9 million transactions in April 2012 increased 22.8% compared to April 2011, increased 14.8% compared to March 2012 and was 17.8% above first quarter 2012 levels.
  • Year-to-date, European cash products ADV of 1.6 million transactions was 5.2% below prior year levels.

 

U.S. Cash

 

  • NYSE Euronext U.S. cash products handled ADV in April 2012 decreased 13.3% to 1.7 billion shares compared to April 2011, decreased 2.5% from March 2012 and was 3.6% below first quarter 2012 levels.
  • Year-to-date, U.S. cash products handled ADV was 1.8 billion shares, down 20.7% from prior year levels.
  • NYSE Euronext's Tape A matched market share in April 2012 was 31.3%, down from 33.3% in April 2011, in-line with March 2012 and above the 30.6% recorded in the first quarter of 2012.

 

Exchange Traded Funds

 

  • NYSE Euronext U.S. matched exchange-traded funds ADV (included in volumes for Tape B and Tape C) of 216 million shares in April 2012 decreased 10.6% compared to April 2011, decreased 2.7% compared to March 2012 and decreased 2.3% compared to the first quarter of 2012.
  • Year-to-date, NYSE Euronext U.S. matched exchange-traded funds ADV of 220 million shares was 19.4% below prior year levels.

 

Please click here for the Monthly Transaction Activity Data Table.

About NYSE Euronext

NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets -- the New York Stock Exchange, NYSE Euronext, NYSE Amex, NYSE Alternext and NYSE Arca -- represent one-third of the worlds equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index. For more information, please visit: www.nyx.com.

Disclaimer and Cautionary Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning NYSE Euronext's plans, objectives, expectations and intentions and other statements that are not historical or current facts. Forward-looking statements are based on NYSE Euronext's current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause NYSE Euronext's results to differ materially from current expectations include, but are not limited to: NYSE Euronext's ability to implement its strategic initiatives, economic, political and market conditions and fluctuations, government and industry regulation, interest rate risk and U.S. and global competition, and other factors detailed in NYSE Euronext's 2011 Annual Report on Form 10-K and other periodic reports filed with the U.S. Securities and Exchange Commission or the French Autorite des Marches Financiers. In addition, these statements are based on a number of assumptions that are subject to change. Accordingly, actual results may be materially higher or lower than those projected. The inclusion of such projections herein should not be regarded as a representation by NYSE Euronext that the projections will prove to be correct. This press release speaks only as of this date. NYSE Euronext disclaims any duty to update the information herein.

1 All NYSE Euronext derivatives transactions count buy and sell orders together as a single transaction. NYSE Euronext European equities transactions count each buy and sell order as separate transactions, NYSE Euronext U.S. equities transactions count buy and sell orders together as a single transaction.

NYSE Euronext

Monthly Volume Summary

                                         
    Average Daily Volume   Total Volume  

Average Daily Volume

  Total Volume
(Unaudited; contracts in thousands)   Apr-12   Apr-11   % Chg   Apr-12   Apr-11   % Chg   YTD 2012  

% Chg vs.

YTD 2011

  YTD 2012  

% Chg vs.

YTD 2011

                                         
Number of Trading Days - European Markets   19   19       19   19       84       84    
Number of Trading Days - U.S. Markets   20   20       20   20       82       82    
                                         
European Derivatives Products   4,270   4,721   -9.6%   81,127   89,699   -9.6%   3,544   -23.8%   297,722   -22.9%
of which Bclear   1,471   1,842   -20.1%   27,945   34,990   -20.1%   853   -16.0%   71,675   -15.0%
                                         
Total Fixed Income Products   1,792   1,929   -7.1%   34,049   36,659   -7.1%   1,778   -29.5%   149,377   -28.7%
                                         
Short Term Interest Rate Products   1,665   1,817   -8.3%   31,636   34,516   -8.3%   1,632   -31.9%   137,074   -31.1%
Medium and Long Term Interest Rate Products 1   127   113   12.7%   2,414   2,143   12.7%   146   15.1%   12,303   16.5%
                                         

Total Equity Products 2

  2,397   2,714   -11.7%   45,538   51,570   -11.7%   1,685   -17.6%   141,512   -16.6%
                                         
Individual Equity Products   1,847   2,254   -18.1%   35,085   42,828   -18.1%   1,206   -19.2%   101,328   -18.2%
Futures   1,325   1,756   -24.6%   25,173   33,369   -24.6%   695   -17.8%   58,347   -16.8%
Options   522   498   4.8%   9,913   9,459   4.8%   512   -20.9%   42,980   -20.0%
Equity Index Products   550   460   19.6%   10,453   8,742   19.6%   478   -13.4%   40,185   -12.3%
                                         
of which Bclear   1,471   1,842   -20.1%   27,945   34,990   -20.1%   853   -16.0%   71,675   -15.0%
Individual Equity Products   1,409   1,785   -21.1%   26,765   33,914   -21.1%   783   -16.8%   65,763   -15.8%
Futures   1,253   1,701   -26.3%   23,816   32,319   -26.3%   672   -18.8%   56,476   -17.9%
Options   155   84   84.9%   2,948   1,594   84.9%   111   -1.4%   9,287   -0.2%
Equity Index Products   62   57   9.7%   1,180   1,076   9.7%   70   -6.7%   5,912   -5.5%
                                         
Commodity Products   81   77   4.7%   1,539   1,470   4.7%   81   -4.9%   6,833   -3.7%
                                         
U.S. Derivatives Products                                        
                                         
Equity Options 3                                        
                                         
NYSE Euronext Options Contracts   3,903   4,034   -3.3%   78,050   80,687   -3.3%   4,073   -5.7%   333,973   -5.7%
Total Consolidated Options Contracts   14,772   15,705   -5.9%   295,434   314,103   -5.9%   15,609   -7.7%   1,279,942   -7.7%
                                         
NYSE Group Share of Total   26.4%   25.7%       26.4%   25.7%       26.1%   0.6%   26.1%   0.6%
                                         
NYSE Liffe U.S.                                        
                                         
Futures and Futures Options Volume*   61.5   91.7   -33.0%   1,291   1,834   -29.6%   87.7   131.7%   7,452.0   134.4%
                                         
European Cash Products (trades in thousands)   1,865   1,519   22.8%   35,444   28,860   22.8%   1,647   -5.2%   138,371   -4.1%
                                         
Equities   1,810   1,461   23.9%   34,385   27,757   23.9%   1,593   -4.6%   133,824   -3.4%
Exchange-Traded Funds   16   16   -0.3%   301   302   -0.3%   15   -24.1%   1,242   -23.2%
Structured Products   35   37   -5.7%   658   697   -5.7%   34   -19.9%   2,893   -19.0%
Bonds   5   5   -3.0%   101   104   -3.0%   5   -9.9%   412   -8.8%
                                         
U.S. Cash Products (shares in millions) 5   1,719   1,982   -13.3%   34,378   39,637   -13.3%   1,768   -20.7%   144,935   -20.7%
                                         
NYSE Listed (Tape A) Issues 4                                        
                                         
Handled Volume 5   1,238   1,409   -12.1%   24,760   28,179   -12.1%   1,266   -21.1%   103,782   -21.1%
Matched Volume 6   1,170   1,330   -12.0%   23,408   26,610   -12.0%   1,194   -21.3%   97,939   -21.3%
Total NYSE Listed Consolidated Volume   3,743   3,995   -6.3%   74,868   79,902   -6.3%   3,886   -12.2%   318,667   -12.2%
                                         
Share of Total Consolidated Volume                                        
Handled Volume 5   33.1%   35.3%   -2.2%   33.1%   35.3%   -2.2%   32.6%   -3.7%   32.6%   -3.7%
Matched Volume 6   31.3%   33.3%   -2.0%   31.3%   33.3%   -2.0%   30.7%   -3.5%   30.7%   -3.5%
                                         
NYSE Arca & Amex (Tape B) Listed Issues                                        
                                         
Handled Volume 5   253   296   -14.5%   5,067   5,923   -14.5%   262   -21.5%   21,507   -21.5%
Matched Volume 6   226   265   -14.5%   4,530   5,295   -14.5%   234   -21.8%   19,200   -21.8%
Total NYSE Arca & Amex Listed Consolidated Volume   1,094   1,154   -5.2%   21,874   23,081   -5.2%   1,116   -14.4%   91,494   -14.4%
                                         
Share of Total Consolidated Volume                                        
Handled Volume 5   23.2%   25.7%   -2.5%   23.2%   25.7%   -2.5%   23.5%   -2.2%   23.5%   -2.2%
Matched Volume 6   20.7%   22.9%   -2.2%   20.7%   22.9%   -2.2%   21.0%   -2.0%   21.0%   -2.0%
                                         
Nasdaq Listed (Tape C) Issues                                        
                                         
Handled Volume 5   228   277   -17.8%   4,552   5,534   -17.8%   240   -17.6%   19,646   -17.6%
Matched Volume 6   192   234   -18.0%   3,832   4,672   -18.0%   203   -18.0%   16,608   -18.0%
Total Nasdaq Listed Consolidated Volume   1,704   1,928   -11.6%   34,074   38,557   -11.6%   1,773   -12.3%   145,404   -12.3%
                                         
Share of Total Consolidated Volume                                        
Handled Volume 5   13.4%   14.4%   -1.0%   13.4%   14.4%   -1.0%   13.5%   -0.9%   13.5%   -0.9%
Matched Volume 6   11.2%   12.1%   -0.9%   11.2%   12.1%   -0.9%   11.4%   -0.8%   11.4%   -0.8%
                                         
Exchange-Traded Funds 5,7                                        
                                         
Handled Volume 5   242   271   -10.5%   4,846   5,413   -10.5%   247   -18.9%   20,253   -18.9%
Matched Volume 6   216   242   -10.6%   4,327   4,838   -10.6%   220   -19.4%   18,045   -19.4%
Total ETF Consolidated Volume   1,074   1,061   1.3%   21,487   21,216   1.3%   1,082   -9.9%   88,685   -9.9%
                                         
Share of Total Consolidated Volume                                        
Handled Volume 5   22.6%   25.5%   -2.9%   22.6%   25.5%   -2.9%   22.8%   -2.5%   22.8%   -2.5%
Matched Volume 6   20.1%   22.8%   -2.7%   20.1%   22.8%   -2.7%   20.3%   -2.4%   20.3%   -2.4%
                                         

1 Data includes currency products.

2 Includes all trading activities for Bclear, NYSE Liffe's clearing service for wholesale derivatives.

3 Includes trading in U.S. equity options contracts, not equity-index options.

4 Includes all volume executed in NYSE Group crossing sessions.

5 Represents the total number of shares of equity securities and ETFs internally matched on the NYSE Group's exchanges or routed to and executed at an external market center. NYSE Arca routing includes odd-lots.

6 Represents the total number of shares of equity securities and ETFs executed on the NYSE Group's exchanges.

7 Data included in previously identified categories.

* ADVs calculated with the appropriate number of NYSE Liffe U.S. trading days.

Source: NYSE Euronext, Options Clearing Corporation and Consolidated Tape as reported for equity securities.
All trading activity is single-counted, except European cash trading which is double counted to include both buys and sells.
Please note: Nasdaq Listed Consolidated Volumes have been adjusted for Nasdaq's April 5th UTDF trade reporting issue.

 

SOURCE: NYSE Euronext